WILLIAM J FEDERICI
CIK 1260426 · Sr. VP & CFO · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$98.50M
Companies
5
Total Filings
134
Lifetime Open-Market Net
-$23.17M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| STVN | Director | 58,580 | $19.75 | $1.16M | -$25.5K | 1 | 2026-06-26 |
| Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Director | 47,824 | $1.30 | $62.2K | -$80 | 17 | 2023-10-11 |
| WST | Sr. VP & CFO | 271,727 | $357.66 | $97.19M | -$23.14M | 100 | 2018-06-11 |
| PATH | Director | 13,500 | $11.80 | $159.3K | $0 | 14 | 2014-01-03 |
| Synvista Therapeutics, Inc. (SYI) Delisted | Director | — | — | — | $0 | 1 | 2008-10-10 |
Recent Filings · Page 3 of 14
134 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-05-18 | WST | Mixed | — | -$4.10M | EDGAR |
| 2017-04-04 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-02-22 | WST | Grant (A) | — | $0 | EDGAR |
| 2017-02-16 | WST | Grant (A) | +4,623 | $401.9K | EDGAR |
| 2016-12-15 | WST | Gift (G) | −3,000 | $0 | EDGAR |
| 2016-07-20 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-03-02 | WST | Gift (G) | −3,205 | $0 | EDGAR |
| 2016-02-25 | WST | Grant (A) | +9,137 | $544.9K | EDGAR |
| 2015-08-19 | WST | Mixed | — | -$1.96M | EDGAR |
| 2015-08-06 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.